Clarapath announced on February 27 its acquisition of Mountain View, California-based Crosscope.
The acquisition combines Clarapath’s SectionStar with Crosscope’s workflow and computational pathology tools enabling labs to deliver care faster, more cost effectively and at a higher quality. Terms of the deal were not disclosed.
Crosscope (abbreviated for “Computational Microscope”) is a digital pathology company with a turnkey imaging solution providing best-in-class workflow tools and slide management along with artificial intelligence and machine learning technology to assist pathologists with faster decision-making.
Clarapath is a medical robotics company aimed at catalyzing change in the way pathology laboratories process human and animal tissue. Clarapath is developing tools and workflow solutions to improve outcomes and reduce costs in clinical and non-clinical pathology. Clarapath’s SectionStar is the first, fully automated, all-in-one tissue sectioning and transfer system. Clarapath is headquartered and runs its medical device development in Hawthorne, New York.
According to data captured in the LevinPro HC database, this acquisition represents the 23rd Laboratories, MRI and Dialysis transaction of 2023 and the fifth in the laboratories subsector.
